Tirzepatide

PHILADELPHIA — Tirzepatide 15 mg produced similar weight loss results as bariatric surgery among patients with obesity but had a favorable safety profile, according to a presenter at the ACG Annual Scientific Meeting.

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the weight-loss medication, a speaker reported.

After decades of research, pharmacologic treatment of obesity gained significant traction with the launch of GLP-1 receptor agonists, and several potentially more potent drugs are currently in the pipeline, a speaker reported.

Ozempic and similar drugs for diabetes and weight-related conditions were associated with a 40% lower rate of opioid overdose and 50% lower rate of alcohol intoxication in people with opioid and alcohol use disorders, a new study showed.

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity.

In this video, David Nathan, MD, discusses the various treatment options for patients with diabetes.

A quarter of adults would consider using an injectable weight loss drug without consulting a health care provider, according to the results of a survey from The Ohio State University Wexner Medical Center.

A recently proposed U.S. Senate bill aims to crack down on social media influencers and others online who make misleading comments about pharmaceutical drugs.

Adults with type 1 diabetes using either semaglutide or tirzepatide off-label had greater decreases in body weight and HbA1c than those not treated with either medication, according to a speaker.